Variation of the Baseline Characteristics and Treatment Parameters over Time: an Analysis of 15 Years of Growth Hormone Replacement in Adults in the German KIMS Database

Overview

Journal Pituitary

Specialty Endocrinology

Date 2012 Jul 26

PMID 22829164

Authors

I Kreitschmann-Andermahr

S Siegel

F Francis

M Buchfelder

H J Schneider

P H Kann

H Wallaschofski

M Koltowska-Haggstrom

G Brabant

Affiliations

Soon will be listed here.

Abstract

The purpose of this study is to examine potential implications of changes in the approach to adult growth hormone (GH) replacement (GHR) over the last 15 years. Therefore, we analysed the German KIMS database as one of the largest single country pharmacoepidemiological databases on adult GH deficiency (GHD). Based on the date of their first GH application patients were assigned to three intervals (1995-1999, 2000-2004, 2005-2009). A multivariate analysis of variance with interval and sex as independent variables was conducted. Differences were analysed with respect to IGF-I standard deviation score (SDS), quality of life, latency between GHD diagnosis and first GH dose, body mass index, waist-hip ratio, lipid profile, and GH dose. All analyses were conducted at baseline, 1 year, and 3 years of GHR. We detected significant associations between time interval and patient characteristics at baseline and with treatment effects. Recently, patients with less severe GHD (mean IGF-I SDS: -2.1, -1.6, -1.0 in the 1st, 2nd and 3rd interval; p = 0.000) are treated with lower GH starting doses (mean 0.30, 0.19, 0.21 mg/day in the 1st, 2nd and 3rd interval; p = 0.000). In the first time interval, IGF-I SDS was not normalized in females after 3 years of GHR. The results of our analysis demonstrate prominent changes in patient characteristics and handling of GHR. They highlight that approach to therapy and patient inclusion criteria change over time and may represent an important confounder for any analysis in epidemiological surveillance surveys.

References

Ho K, Evans W, BLIZZARD R, Veldhuis J, Merriam G, SAMOJLIK E . Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 1987; 64(1):51-8. DOI: 10.1210/jcem-64-1-51. View

Cook D, Yuen K, Biller B, Kemp S, Vance M . American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update: executive summary of recommendations. Endocr Pract. 2009; 15(6):580-6. DOI: 10.4158/EP.15.6.580. View

Maiter D, Abs R, Johannsson G, Scanlon M, Jonsson P, Wilton P . Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur J Endocrinol. 2006; 155(2):253-60. DOI: 10.1530/eje.1.02209. View

Gutierrez L, Koltowska-Haggstrom M, Jonsson P, Mattsson A, Svensson D, Westberg B . Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf. 2007; 17(1):90-102. DOI: 10.1002/pds.1510. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Ho K . Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of.... Eur J Endocrinol. 2007; 157(6):695-700. DOI: 10.1530/EJE-07-0631. View

. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 1998; 83(2):379-81. DOI: 10.1210/jcem.83.2.4611. View

Grimberg A, Stewart E, Wajnrajch M . Gender of pediatric recombinant human growth hormone recipients in the United States and globally. J Clin Endocrinol Metab. 2008; 93(6):2050-6. PMC: 2435638. DOI: 10.1210/jc.2007-2617. View

Brabant G, Poll E, Jonsson P, Polydorou D, Kreitschmann-Andermahr I . Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations?. Eur J Endocrinol. 2009; 161 Suppl 1:S25-31. DOI: 10.1530/EJE-09-0273. View

10.

Kelestimur F, Jonsson P, Molvalilar S, Gomez J, Auernhammer C, Colak R . Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database. Eur J Endocrinol. 2005; 152(4):581-7. DOI: 10.1530/eje.1.01881. View

11.

Kreitschmann-Andermahr I, Poll E, Reineke A, Gilsbach J, Brabant G, Buchfelder M . Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database. Growth Horm IGF Res. 2008; 18(6):472-8. DOI: 10.1016/j.ghir.2008.08.007. View

12.

Grande G . [Gender-specific aspects in health care delivery and rehabilitation after an acute myocardial infarction]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008; 51(1):36-45. DOI: 10.1007/s00103-008-0417-9. View

13.

Spielhagen C, Schwahn C, Moller K, Friedrich N, Kohlmann T, Moock J . The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res. 2010; 21(1):1-10. DOI: 10.1016/j.ghir.2010.10.005. View

14.

Brabant G . Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol. 2003; 148 Suppl 2:S15-20. DOI: 10.1530/eje.0.148s015. View

15.

Lissett C, Jonsson P, Monson J, Shalet S . Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol (Oxf). 2004; 59(6):773-8. DOI: 10.1046/j.1365-2265.2003.01884.x. View

16.

Lie R, Schmitz J, Pierre K, GOCHMAN N . Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem. 1976; 22(10):1627-30. View

17.

McKenna S, Doward L, Alonso J, Kohlmann T, Niero M, Prieto L . The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res. 1999; 8(4):373-83. DOI: 10.1023/a:1008987922774. View

18.

Bengtsson B, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G . Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993; 76(2):309-17. DOI: 10.1210/jcem.76.2.8432773. View

19.

Abs R, Bengtsson B, Monson J, Tauber J, Wilton P, Wuster C . GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999; 50(6):703-13. DOI: 10.1046/j.1365-2265.1999.00695.x. View

20.

Nguyen H, Saczynski J, Gore J, Goldberg R . Age and sex differences in duration of prehospital delay in patients with acute myocardial infarction: a systematic review. Circ Cardiovasc Qual Outcomes. 2010; 3(1):82-92. PMC: 3072277. DOI: 10.1161/CIRCOUTCOMES.109.884361. View